Number of patients with rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and other arthritides in DANBIO with a history of cervical dysplasia (CD) or carcinoma in situ of the cervix (CIS) prior to DANBIO entry
| Treatment | ||||||||
|---|---|---|---|---|---|---|---|---|
| Ever bDMARD*† | Never bDMARD* | |||||||
| Total | CIS | CD | Unspecified§ | Total | CIS | CD | Unspecified§ | |
| Rheumatological diagnosis, n | ||||||||
| All | 327 | 98 | 183 | 46 | 598 | 165 | 357 | 76 |
| RA | 233 | 76 | 118 | 39 | 442 | 138 | 241 | 63 |
| AS | 17 | 5 | 12 | 0 | 16 | 3 | 13 | 0 |
| PsA | 45 | 11 | 30 | 4 | 91 | 18 | 64 | 9 |
| Other‡ | 32 | 6 | 23 | 3 | 49 | 6 | 39 | 4 |
| Characteristics of cohort | ||||||||
| Age at start of follow-up, years | 52.3 (43.2–59.1) | 53.4 (44.6–62.5) | ||||||
| Age at rheumatological diagnosis, years | 44 (35–53) | 48 (39–56) | ||||||
| Time from prior CD/CIS to start of follow-up for entire cohort, years | 15.8 (5.9–23.7) | 16.2 (5.3–25.0) | ||||||
| Time from prior CD/CIS to start of follow-up among patients with RA, years | 17.6 (10.5–24.3) | 18.7 (10.3–26.7) | ||||||
| Proportion with CD/CIS within 2 years prior to start of follow-up, n (%) | 21 (6) | 38 (6) | ||||||
| Follow-up time, years | 3.5 (1.8–6.2) | 1.5 (0.6–3.1) | ||||||
| Person-years of observation | 1303 | 1197 | ||||||
| Treated with csDMARD, n (%) | 220 (67%) | 389 (65%) | ||||||
| Characteristics of patients with RA at start of follow-up | ||||||||
| IgM RF seropositive, n (%) | 175 (75) | 305 (69) | ||||||
| Disease duration, years | 6 (2–14) | 5 (1–10) | ||||||
| Proportion with disease duration <2 years, n (%) | 42 (18) | 111 (25) | ||||||
| Tender joint count (0–28) | 8 (4–14) | 4 (1–8) | ||||||
| Swollen joint count (0–28) | 5 (2–9) | 2 (0–5) | ||||||
| CRP, mg/L | 10 (4–25) | 7 (4–13) | ||||||
| DAS28-CRP | 4.9 (3.7–5.7) | 3.0 (1.2–4.5) | ||||||
| HAQ (0–3) | 1.3 (0.6–1.8) | 0.6 (0.0–1.3) | ||||||
Characteristics of the cohort and clinical characteristics of patients with RA at first registration according to ever or never biological DMARD (bDMARD) exposure.
Numbers are medians (IQR) unless otherwise indicated.
*One hundred and nineteen patients who received csDMARD at DANBIO entry but later switched to bDMARD contributed person-years to both treatment groups and are included in both groups in the table.
†First biological treatment for patients with RA: adalimumab 66 patients; etanercept 53; infliximab 81, golimumab 7 and certolizumab 8; abatacept 0; anakinra 4; rituximab 5; tocilizumab 3 and other 6.
‡Other arthritides: This term covers a range of unspecified inflammatory arthritides.
§A total of 127 patients with precancerous cervical lesions had no specified histopathologic grading in The Danish Cancer Registry.
CRP, C reactive protein; csDMARD, conventional synthetic DMARD; DAS28, Disease Activity Score with 28 joint count; DMARD, disease-modifying antirheumatic drug; HAQ, Health Assessment Questionnaire; RF, rheumatoid factor.